GW Pharmaceuticals secures official NICE approval for EPIDYOLEX®
Category: #health  | By Mateen Dalal  | Date: 2019-11-11 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

GW Pharmaceuticals secures official NICE approval for EPIDYOLEX®

GW Pharmaceuticals plc has reportedly announced that two of its medicines, Sativex (nabiximols) and EPIDYOLEX (cannabidiol) oral solution, have been advised by National Institute for Health and Care Excellence (NICE) of the U.K. to get routine compensation from NHS England.

Apparently, for the first-time any plant-derived cannabis-based drug has been advised by NICE for use on NHS. Cannabidiol oral solution is suggested as an adjunctive treatment for seizures related to Dravet syndrome or Lennox Gastaut syndrome (LGS), in conjunction with clobazam, for patients aged two years and older. In addition, Nabiximols, assessed as part of NICE’s analysis of cannabis-based medicinal products (CBMPs), has been considered economical for treatment of spasticity caused by multiple sclerosis.

Chris Tovey, Chief Operating Officer, GW, reportedly stated that this is a significant event for patients and families in the U.K. who have waited since a very long time for rigorously tested, proved and regulatory approved cannabis-based medication to be reimbursed by NHS. The recommendation by NICE has proved that cannabis-based drugs can effectively go through extensive randomized placebo-controlled tests and a rigorous evaluation process of NICE to reach patients.

Reportedly, cannabidiol oral solution has secured approval based on outcomes from four randomized, controlled Phase III studies. These trials include data from over 714 patients with either Dravet or LGS syndrome. Both the diseases are two rare forms of epilepsy with high mortality and morbidity rates, which considerably burdens caregivers and families. Several patients with Dravet or LGS syndrome go through multiple seizures per day, which increase the ongoing risk of injury and falls. Regardless of current anti-epileptic drug therapy, both of these rare forms of epilepsy have remained as extremely treatment resistant.

According to reliable sources, after the approval, GW has been functioning with the related bodies in Germany, the U.K., Spain, Italy, and France. The company intends to obtain reimbursement before anticipated launch of medication in these nations.
 

Source credits:

http://ir.gwpharm.com/news-releases/news-release-details/gw-pharmaceuticals-receives-positive-nice-recommendation

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Pintarnya to develop a super app for blue collar workers in Indonesia

Pintarnya to develop a super app for blue collar workers in Indonesia

By Mateen Dalal

Pintarnya, a job upskilling platform based out of Indonesia, has reportedly announced that it plans to develop a new app for the 60 million blue-collar workers of Indonesia who often face uncertainty and scams while looking for a job. As per repor...

UK’s Health Secretary announces 10-year plan to tackle dementia

UK’s Health Secretary announces 10-year plan to tackle dementia

By Mateen Dalal

The UK Health and Social Care Secretary, Sajid Javid, has reportedly announced a novel 10-year plan to effectively tackle dementia and to increase funding in research to get a better understanding of neurodegenerative diseases. As per sources, at ...

Starbucks to cover abortion related travel expenses for workers

Starbucks to cover abortion related travel expenses for workers

By Mateen Dalal

Starbucks has reportedly announced that it would start covering all eligible travel expenditures for the workers seeking gender-affirming surgical procedures or abortions. As per reports, the coffee conglomerate has joined Apple, Amazon, Salesforc...